For the Inventor, By the Inventor

Enter assignee name

London, United Kingdom

Lipoxen Technologies Incorporated

USPTO Granted Patents = 57

EPO Patents = 15

Trademarks = 2

Forward Citations = 196

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

Sanjay Jain (43 out of 44 patents)

Gregory Gregoriadis (37 out of 40 patents)

Peter Laing (36 out of 36 patents)

4. Ioannis Papaioannou (22 out of 22 patents)

5. Smita Thobhani (10 out of 10 patents)

6. Norbert Oskar Rumpf (8 out of 8 patents)

7. Dale Howard Hreczuk-Hirst (7 out of 8 patents)

8. Andrew David Bacon (6 out of 7 patents)

9. Wilson Romero Caparros-Wanderley (4 out of 28 patents)

10. Hanspeter Rottensteiner (2 out of 35 patents)

11. Peter Turecek (2 out of 119 patents)

12. Juergen Siekmann (2 out of 44 patents)

13. Stefan Haider (2 out of 13 patents)

14. Archana Dwivedi (2 out of 2 patents)

15. Srijit Nath (2 out of 2 patents)

Core Competencies:

Polysialic Acid Derivatives

Sialic Acid Derivatives

Glycopolysialylation

N-Terminal Polysialylation

Liposomal Vaccine Compositions

Erythropoietin Derivatisation

Granulocyte Colony-Stimulating Factor

Charged Polysaccharide Fractionation

Immune Response Enhancement

Histones Therapeutic Use

Protein Adjuvant

Nucleic Acid Vaccination

57 patents: Sort by Forward Citations

1. 10772968 - Glycopolysialylation of non-blood coagulation proteins (2020-09-15),

2. 10494449 - Fractionation of charged polysaccharide (2019-12-03),

3. 10406209 - Sialic acid derivatives for protein derivatisation and conjugation (2019-09-10),

4. 10406150 - Method for treatment of primary hormone resistant endometrial and breast cancers (2019-09-10),

5. 10301396 - Reduction of endotoxin in polysialic acids (2019-05-28),

6. 10300144 - N-terminal polysialylation (2019-05-28),

7. 10155046 - Activated sialic acid derivatives for protein derivatisation and conjugation (2018-12-18),

8. 10155045 - Activated sialic acid derivatives for protein derivatisation and conjugation (2018-12-18),

9. 9920137 - Polysialic acid derivatives (2018-03-20),

10. 9828443 - Fractionation of charged polysaccharide (2017-11-28),

11. 9795683 - Glycopolysialylation of non-blood coagulation proteins (2017-10-24),

12. 9790288 - Fractionation of charged polysaccharide (2017-10-17),

13. 9789163 - N-terminal derivatisation of proteins with polysaccharides (2017-10-17),

14. 9750692 - Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant (2017-09-05),

15. 9579393 - Derivatisation of erythropoietin (EPO) (2017-02-28),

Lipoxen Technologies Incorporated is a biotechnology company specializing in the development of advanced liposomal drug delivery systems. With a focus on enhancing the efficacy, safety, and delivery of therapeutic compounds, Lipoxen aims to revolutionize the field of drug delivery. Their innovative solutions have the potential to improve patient outcomes and address unmet medical needs across various therapeutic areas.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

57 Patents

#59 in London

#301 in United Kingdom

#12,285 in the World

London, United Kingdom

Lipoxen Technologies Incorporated

Forward Citations = 196

23 inventors:

Sanjay Jain (43 out of 44 patents)

Gregory Gregoriadis (37 out of 40 patents)

Peter Laing (36 out of 36 patents)

4. Ioannis Papaioannou (22 out of 22 patents)

5. Smita Thobhani (10 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…